Haemodialysis patient with chronic kidney disease and pulmonary hypertension treated effectively with pulmonary vasodilators
Abstract
A male patient in his 70s on periodic haemodialysis complained of dysdialysis several months prior and was diagnosed subsequently with pulmonary hypertension (PH). To confirm this diagnosis, a catheter examination was performed after haemodialysis in the dry state. Pulmonary artery wedge pressure (PAWP), mean pulmonary artery (PA) pressure, cardiac index (CI) and pulmonary vascular resistance (PVR) were 9 mm Hg, 42 mm Hg, 2.63 L/min/m2 and 5.9 WU, respectively. The pathophysiological diagnosis was precapillary PH, which mimicked idiopathic PH. The pulmonary vasodilators were administered in a careful sequential manner. After initiation of therapy, dysdialysis disappeared within a few months, while mean PA pressure, CI and PVR improved to 24 mm Hg, 3.47 L/min/m2 and 2.3 WU, respectively. Although the cause of PH in haemodialysis patients is multifactorial, catheter examination in the dry state is useful for clarifying a patient's haemodynamic state. In a haemodialysis PH patient with precapillary PH, pulmonary vasodilators are an effective treatment option.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.